New intravenous iron replacement therapies

Clinical Advances in Hematology and Oncology

Volumn 8, Issue 10, 2010, Pages 688-689

  Auerbach, Michael ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; CORTICOSTEROID; DIPHENHYDRAMINE; FERAHEME; FERINJECT; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERUMOXYTOL; IRON; IRON CARBOXYMALTOSE; IRON DEXTRAN; IRON ISOMALTOSIDE; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CANCER PATIENT; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; HUMAN; HYPOPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; OUTCOME ASSESSMENT; PATIENT EDUCATION; PRESCRIPTION; SOMNOLENCE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ANEMIA, IRON-DEFICIENCY; HUMANS; INFUSIONS, INTRAVENOUS; IRON COMPOUNDS; NEOPLASMS;

EID: 78649935229     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Auerbach M, Goodnough LT, Picard D, Maniatis A. The role of intravenous iron in anemia management and transfusion avoidance. Transfusion. 2008;48: 988-1000.
2. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008;26:1611-1618.
3. Kim YT, Kim SW, Yoon BS, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol. 2007;105:199-204.
4. Barton JC, Barton EH, Bertoli LF, Gothard CH, Sherrer JS. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med. 2000;109:27-32.